146 related articles for article (PubMed ID: 37708455)
1. GALAD outperforms aMAP and ALBI for predicting HCC in patients with compensated advanced chronic liver disease: A 12-year prospective study.
Villa E; Donghia R; Baldaccini V; Tedesco CC; Shahini E; Cozzolongo R; Ascari S; Pesole PL; Coletta S; Critelli RM; Lasagni S; Schepis F; Semellini F; Giannelli G
Hepatol Commun; 2023 Oct; 7(10):. PubMed ID: 37708455
[TBL] [Abstract][Full Text] [Related]
2. GALAD Score Detects Early Hepatocellular Carcinoma in an International Cohort of Patients With Nonalcoholic Steatohepatitis.
Best J; Bechmann LP; Sowa JP; Sydor S; Dechêne A; Pflanz K; Bedreli S; Schotten C; Geier A; Berg T; Fischer J; Vogel A; Bantel H; Weinmann A; Schattenberg JM; Huber Y; Wege H; von Felden J; Schulze K; Bettinger D; Thimme R; Sinner F; Schütte K; Weiss KH; Toyoda H; Yasuda S; Kumada T; Berhane S; Wichert M; Heider D; Gerken G; Johnson P; Canbay A
Clin Gastroenterol Hepatol; 2020 Mar; 18(3):728-735.e4. PubMed ID: 31712073
[TBL] [Abstract][Full Text] [Related]
3. The Performance of AFP, AFP-3, DCP as Biomarkers for Detection of Hepatocellular Carcinoma (HCC): A Phase 3 Biomarker Study in the United States.
Tayob N; Kanwal F; Alsarraj A; Hernaez R; El-Serag HB
Clin Gastroenterol Hepatol; 2023 Feb; 21(2):415-423.e4. PubMed ID: 35124267
[TBL] [Abstract][Full Text] [Related]
4. Surveillance and treatment of primary hepatocellular carcinoma (aka. STOP HCC): protocol for a prospective cohort study of high-risk patients for HCC using GALAD-score.
Truong TN; Pham TND; Hoang LB; Nguyen VT; Dao HV; Dao DVB; Alessy S; Pham HB; Pham TTT; Nguyen LDD; Nguyen K; Abaalkhail F; Manal M; Mawardi M; AlZahrani M; Alswat K; Alghamdi H; Sanai FM; Siddiqui MA; Nguyen NH; Vaidya D; Phan HT; Johnson PJ; Alqahtani SA; Dao DY
BMC Cancer; 2023 Sep; 23(1):875. PubMed ID: 37723439
[TBL] [Abstract][Full Text] [Related]
5. Validation and optimization of AFP-based biomarker panels for early HCC detection in Latin America and Europe.
Beudeker BJB; Fu S; Balderramo D; Mattos AZ; Carrera E; Diaz J; Prieto J; Banales J; Vogel A; Arrese M; Oliveira J; Groothuismink ZMA; van Oord G; Hansen BE; de Man RA; Debes JD; Boonstra A
Hepatol Commun; 2023 Oct; 7(10):. PubMed ID: 37708457
[TBL] [Abstract][Full Text] [Related]
6. Galad Score as a Prognostic Marker for Patients with Hepatocellular Carcinoma.
Cagnin S; Donghia R; Martini A; Pesole PL; Coletta S; Shahini E; Boninsegna G; Biasiolo A; Pontisso P; Giannelli G
Int J Mol Sci; 2023 Nov; 24(22):. PubMed ID: 38003675
[TBL] [Abstract][Full Text] [Related]
7. GALAD demonstrates high sensitivity for HCC surveillance in a cohort of patients with cirrhosis.
Singal AG; Tayob N; Mehta A; Marrero JA; El-Serag H; Jin Q; Saenz de Viteri C; Fobar A; Parikh ND
Hepatology; 2022 Mar; 75(3):541-549. PubMed ID: 34618932
[TBL] [Abstract][Full Text] [Related]
8. Role of the GALAD and BALAD-2 Serologic Models in Diagnosis of Hepatocellular Carcinoma and Prediction of Survival in Patients.
Berhane S; Toyoda H; Tada T; Kumada T; Kagebayashi C; Satomura S; Schweitzer N; Vogel A; Manns MP; Benckert J; Berg T; Ebker M; Best J; Dechêne A; Gerken G; Schlaak JF; Weinmann A; Wörns MA; Galle P; Yeo W; Mo F; Chan SL; Reeves H; Cox T; Johnson P
Clin Gastroenterol Hepatol; 2016 Jun; 14(6):875-886.e6. PubMed ID: 26775025
[TBL] [Abstract][Full Text] [Related]
9. Refinement and validation of a comprehensive clinical diagnostic model (GAMAD) based on gender, age, multitarget circulating tumour DNA methylation signature and commonly used serological biomarkers for early detection of hepatocellular carcinoma: a multicentre, prospective observational study protocol.
Yang T; Wang N; Wang F; Liu H; Shen F; Lv G
BMJ Open; 2023 Sep; 13(9):e076467. PubMed ID: 37723113
[TBL] [Abstract][Full Text] [Related]
10. Applicability of BALAD score in prognostication of hepatitis B-related hepatocellular carcinoma.
Chan SL; Mo F; Johnson P; Li L; Tang N; Loong H; Chan AW; Koh J; Chan AT; Yeo W
J Gastroenterol Hepatol; 2015 Oct; 30(10):1529-35. PubMed ID: 25968302
[TBL] [Abstract][Full Text] [Related]
11. GALAD Score Detects Early-Stage Hepatocellular Carcinoma in a European Cohort of Chronic Hepatitis B and C Patients.
Schotten C; Ostertag B; Sowa JP; Manka P; Bechmann LP; Hilgard G; Marquardt C; Wichert M; Toyoda H; Lange CM; Canbay A; Johnson P; Wedemeyer H; Best J
Pharmaceuticals (Basel); 2021 Jul; 14(8):. PubMed ID: 34451832
[TBL] [Abstract][Full Text] [Related]
12. Novel, high accuracy models for hepatocellular carcinoma prediction based on longitudinal data and cell-free DNA signatures.
Fan R; Chen L; Zhao S; Yang H; Li Z; Qian Y; Ma H; Liu X; Wang C; Liang X; Bai J; Xie J; Fan X; Xie Q; Hao X; Wang C; Yang S; Gao Y; Bai H; Dou X; Liu J; Wu L; Jiang G; Xia Q; Zheng D; Rao H; Xia J; Shang J; Gao P; Xie D; Yu Y; Yang Y; Gao H; Liu Y; Sun A; Jiang Y; Yu Y; Niu J; Sun J; Wang H; Hou J
J Hepatol; 2023 Oct; 79(4):933-944. PubMed ID: 37302583
[TBL] [Abstract][Full Text] [Related]
13. Performance of GALAD score and serum biomarkers for detecting NAFLD-related HCC: a systematic review and network meta-analysis.
Li H; Liu H; Yan LJ; Ding ZN; Zhang X; Pan GQ; Han CL; Tian BW; Tan SY; Dong ZR; Wang DX; Yan YC; Li T
Expert Rev Gastroenterol Hepatol; 2023; 17(11):1159-1167. PubMed ID: 37929312
[TBL] [Abstract][Full Text] [Related]
14. HCC risk stratification after cure of hepatitis C in patients with compensated advanced chronic liver disease.
Semmler G; Meyer EL; Kozbial K; Schwabl P; Hametner-Schreil S; Zanetto A; Bauer D; Chromy D; Simbrunner B; Scheiner B; Stättermayer AF; Pinter M; Schöfl R; Russo FP; Greenfield H; Schwarz M; Schwarz C; Gschwantler M; Alonso López S; Manzano ML; Ahumada A; Bañares R; Pons M; Rodríguez-Tajes S; Genescà J; Lens S; Trauner M; Ferenci P; Reiberger T; Mandorfer M
J Hepatol; 2022 Apr; 76(4):812-821. PubMed ID: 34871626
[TBL] [Abstract][Full Text] [Related]
15. Chinese expert consensus statement on the clinical application of AFP/AFP-L3%/DCP using GALAD and GALAD-like algorithm in HCC.
Huang C; Xiao X; Zhou L; Chen F; Wang J; Hu X; Gao C;
J Clin Lab Anal; 2023 Dec; 37(23-24):e24990. PubMed ID: 38063322
[TBL] [Abstract][Full Text] [Related]
16. The GALAD scoring algorithm based on AFP, AFP-L3, and DCP significantly improves detection of BCLC early stage hepatocellular carcinoma.
Best J; Bilgi H; Heider D; Schotten C; Manka P; Bedreli S; Gorray M; Ertle J; van Grunsven LA; Dechêne A
Z Gastroenterol; 2016 Dec; 54(12):1296-1305. PubMed ID: 27936479
[No Abstract] [Full Text] [Related]
17. Multimarker Panels for Detection of Early Stage Hepatocellular Carcinoma: A Prospective, Multicenter, Case-Control Study.
Piratvisuth T; Tanwandee T; Thongsawat S; Sukeepaisarnjaroen W; Esteban JI; Bes M; Köhler B; He Y; Swiatek-de Lange M; Morgenstern D; Chan HL
Hepatol Commun; 2022 Apr; 6(4):679-691. PubMed ID: 34796691
[TBL] [Abstract][Full Text] [Related]
18. The GALAD score and the BALAD-2 score correlate with transarterial and systemic treatment response and survival in patients with hepatocellular carcinoma.
Olbrich A; Niemeyer J; Seiffert H; Ebel S; Gros O; Lordick F; Forstmeyer D; Seehofer D; Rademacher S; Denecke T; Matz-Soja M; Berg T; van Bömmel F
J Cancer Res Clin Oncol; 2024 Feb; 150(2):81. PubMed ID: 38319485
[TBL] [Abstract][Full Text] [Related]
19. Validation and prognostic value of EZ-ALBI score in patients with intermediate-stage hepatocellular carcinoma treated with trans-arterial chemoembolization.
Ananchuensook P; Sriphoosanaphan S; Suksawatamnauy S; Siripon N; Pinjaroen N; Geratikornsupuk N; Kerr SJ; Thanapirom K; Komolmit P
BMC Gastroenterol; 2022 Jun; 22(1):295. PubMed ID: 35701739
[TBL] [Abstract][Full Text] [Related]
20. Diagnostic value of AFP-L3 and PIVKA-II in hepatocellular carcinoma according to total-AFP.
Choi JY; Jung SW; Kim HY; Kim M; Kim Y; Kim DG; Oh EJ
World J Gastroenterol; 2013 Jan; 19(3):339-46. PubMed ID: 23372355
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
